T-cell acute lymphoblastic leukemia as a secondary leukemia after a 3-year remission of acute myelocytic leukemia.
Therapy-related myelodysplastic syndrome and therapy-related acute myelocytic leukemia (AML) are now recognized as hematologic malignancies that occur a few years after chemotherapy for primary malignancy with alkylating agents or topoisomerase II inhibitors. The secondary leukemia is usually AML and sometimes is preceded by a myelodysplastic syndrome. Acute lymphoblastic leukemia (ALL) as a secondary leukemia is quite rare, and secondary T-cell ALL after AML is even rarer. We report a case of a 56-year-old woman who developed T-cell ALL after a 3-year remission of AML (M2). We thought that this case would be extremely valuable for studying the etiology and biological characteristics of T-cell ALL as a secondary leukemia after AML.
Tsuboi
Kazuya
K
Second Department of Internal Medicine, Nagoya City University Medical School, Japan. tsuboi@pf6.so-net.ne.jp
Komatsu
Hirokazu
H
Miwa
Hiroshi
H
Iida
Shinsuke
S
Banno
Shougo
S
Wakita
Atsushi
A
Nitta
Masakazu
M
Ueda
Ryuzo
R
D002883:Chromosomes, Human, Pair 14; D002896:Chromosomes, Human, Pair 6; D005260:Female; D015321:Gene Rearrangement; D019672:Genes, T-Cell Receptor; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000473:pathology*; D015458:Leukemia, T-Cell / Q000175:diagnosis / Q000209:etiology* / Q000235:genetics; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000209:etiology* / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000209:etiology* / Q000235:genetics; D012074:Remission Induction; D014178:Translocation, Genetic